Point72 Asset Management
REGN icon

Point72 Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Point72 Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$111M Buy
143,800
+142,900
+15,878% +$109M 0.14% 150
2025
Q4 		$695K Buy
+900
New +$611K ﹤0.01% 3064
2024
Q4 		– Sell
-2,200
Closed -$2.31M – 2387
2024
Q3 		$2.31M Buy
+2,200
New +$2.45M 0.01% 1141

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Point72 Asset Management's REGN Position: Q1 2026 in Review

Point72 Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 99% in Q1 2026, selling an estimated $199M and leaving 2,175 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #2436.

Point72 Asset Management first reported a position in REGN in Q2 2014 and has held it in 18 quarters since. The position peaked at $203M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Point72 Asset Management held 2,175 shares of Regeneron Pharmaceuticals worth $1.68M as of Q1 2026.
  • Point72 Asset Management sold 260,352 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $199M.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2436 holding.
  • Point72 Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 18 quarters since.
  • Point72 Asset Management's Regeneron Pharmaceuticals position peaked at $203M in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.